Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with relapsed PTCL according to WHO criteria who have received max. two previous treatments for PTCL~* Age ≥ 18 years.~* Adequate bone marrow function i.e. absolute neutrophile count of \> 1000/µl and thrombocytes \> 75,000/µl.~* Alkaline phosphatase and transaminases ≤ 2,5 x upper limit of normal (ULN)~* Total bilirubin ≤ 2,5 x ULN~* Creatinine clearance ≥ 50 ml/min~* Female subjects of childbearing potential† must: Understand that the study medication could have an expected teratogenic risk and agree to use, and be able to comply with, effective contraception and agree to have a medically supervised pregnancy test~* Male subjects must agree to use condoms and agree not to donate semen~Exclusion Criteria:~* Prior history of malignancies, other than PTCL, unless the subject has been free of the disease for ≥ 3 years~* Prior allogeneic bone marrow transplant or plans to undergo autologous/ allogeneic bone marrow transplant within 4 weeks of the initiation of vorinostat administration~* Prior treatment with a HDAC inhibitor~* Prior treatment with Lenalidomide (patients previously treated with Thalidomide may be enrolled)~* Known history of Deep Vein Thrombosis (DVT) and/ or pulmonary embolism (PE)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).